The role of the p38 signaling pathway in the innate and adaptive immune responses has been well documented, especially in inflammatory cytokine production by dendritic cells (DCs). However, whether the p38 signaling pathway affects the important antigen (Ag) presentation function of DCs remains largely unknown. In this study, we reported that the deletion of p38α resulted in an impaired cross-presentation ability of CD8 + conventional DCs (cDCs) and a reduction in the direct presentation ability of CD8 − cDCs ex vivo. Further study revealed that p38α had a crucial role in Ag processing by CD8 + cDCs but did not affect the Ag uptake or co-stimulation of T cells. Moreover, p38α deficiency led to reduced cross-priming of T cells in vivo. The production of the IL-12p40 and IL-12p70 cytokines by p38α-deficient cDCs was also significantly reduced. Our study identified a new role for p38α in modulating the important antigen cross-presentation function of DCs.
INTRODUCTION
Dendritic cells (DCs) are the most efficient antigen (Ag)-presenting cells and link innate and adaptive immunity. DCs have an important role in immune responses to infections and maintain immune tolerance to self tissues. Although all DCs have the ability to present Ags to naive T cells, they differ in their surface markers, localization and cytokine production. 1 At steady state, DCs in the mouse lymphoid organs can be categorized as plasmacytoid DCs (pDCs) and conventional DCs (cDCs, CD8 + cDCs and CD8 -cDCs). 2 pDCs can produce a large amount of type-I interferon (IFN) upon activation but have a weak Ag presenting ability, whereas 3 the cDCs are very efficient in Ag presentation and express high levels of the MHC-I and MHC-II molecules. 4 DCs uptake Ag through endocytosis or phagocytosis. 5 The Ags are degraded into peptides that form peptide/MHC complexes, which are expressed on the DC surface for presentation to T cells. 6 Classically, endogenous Ag peptides are bound to MHC-I molecules for presentation to CD8 + T cells, whereas exogenous Ags are presented to CD4 + T cells via the MHC-II presentation pathway. 7 These two Ag presentation pathways are known as direct presentation. Moreover, there is an interesting link between the two pathways, which is referred to as Ag cross-presentation, whereby exogenous Ags are presented by MHC-I molecules to CD8 + T cells to induce cytotoxic T lymphocyte (CTL) responses. 8 Signals in addition to stimulation by the peptide-MHC-I complex are required for T-cell activation and proliferation, including co-stimulation, adhesion and cytokines. 9 Although Ag presentation is a common function of DCs, different DC subsets use specialized Ag presentation pathways. Both CD8 + and CD8 − cDCs capture exogenous Ags efficiently and present them through the MHC-II pathway, but only the CD8 + cDCs can cross-present extracellular Ag on MHC-I molecules. 10 Moreover, the cross-presentation ability of different DC subsets can be regulated by certain cytokines involved in DC development and maturation, 11 and immature CD8 + cDCs have a limited cross-presentation ability compared with mature CD8 + cDCs. 12, 13 Although Ag cross-presentation has been described for many years, the molecules and signaling pathways that regulate this unique function of DCs are not understood completely.
Many studies have revealed that the p38 signaling pathway in DCs has essential roles in inducing innate and adaptive immune responses. 14 A number of studies proposed a strong link between p38 signaling and inflammation. 15 In particular, the p38 inhibitor almost completely abrogated the production of IL-6, IL-12p40, IL-12p70 and TNF-α from LPS-induced monocyte-derived DCs (MoDCs). 16 The p38 pathway is required for the maturation of MoDCs because drug-induced inhibition of this pathway prevents LPS-and TNF-α-induced DC maturation. 17 Moreover, TLR-induced activation of p38 might also participate in the regulation of DC Ag presentation. 18 However, because targeted inactivation of the mouse p38α gene resulted in embryonic lethality, 19 most studies are based on the use of pharmacological inhibitors and only limited data are available from these studies. Although p38α has been reported to program DCs to drive Th17 cell differentiation 20 and regulate T-regulatory-cell functions, 21, 22 the roles of p38α in DC Ag cross-presentation and T-cell activation have not been established.
In this study, we investigated the effect of genetic deletion of p38α on DC functions using DC-specific p38α-deficient mice. We found that the deletion of p38α resulted in an impaired cross-presentation ability of CD8 + cDCs and a reduction in the direct presentation ability of CD8 − cDCs ex vivo. Moreover, p38α deficiency reduced cross-priming of T cells in vivo. Further analysis demonstrated that p38α deficiency impaired the Ag degradation process and antigen-peptide/MHC-I complex formation but did not affect Ag uptake or the expression of costimulatory molecules. The production of IL-12p40 and IL-12p70 by p38α-deficient cDCs was also significantly reduced. Overall, our study demonstrated for the first time an important role for p38α in Ag presentation by DCs at steady state.
MATERIALS AND METHODS
Mice C57BL/6J mice were housed in a specific pathogen-free facility at Tsinghua University, Beijing, China. The p38α fl/fl mice were generated as previously described 23 and backcrossed to the C57BL/6J background for at least eight generations. Floxed p38α mice were bred with CD11c-Cre (Jackson stock 008068, B6.Cg-Tg (Itgax-cre) 1-1Reiz/J) and Vav-cre (Jackson stock 008610, B6.Cg-Tg (Vav1-cre) A2kio/J) mice to generate DCspecific p38α-deficient (p38α ΔDC ) and hematopoietic cellspecific p38α-deficient mice (p38α ΔHPC ), respectively. The Cre-negative littermates were used as the controls. The OT-I transgenic mice (Jackson stock 003831, C57BL/6-Tg (TcraTcrb) 1100Mjb/J) and OT-II transgenic mice 24 were maintained.
Isolation of splenic DCs
To isolate DCs from the spleen, the tissue was minced with scissors and digested with 0.1 mg/mL DNase I (Roche Molecular Biochemicals, Indianapolis, IN, USA) and 1 mg/ml collagenase III (Worthington Biochemical, Lakewood, NJ, USA) at 37°C for 25 min. Then, light density cells were isolated in 1.077 g/cm 3 Nycodenz (Axis-Shield, Scotland, UK) medium by centrifugation for 10 min at 1700g. The light density splenocytes were incubated with mAbs against CD3, CD90, TER119, Ly6G and CD19, followed by removal of non-DC cells using anti-immunoglobulin (Ig)-coated magnetic beads (Bangs Laboratories, Fishers, IN, USA). 25 The enriched cells were stained with fluorescence-conjugated antibodies against DC-specific markers and sorted by flow cytometry.
Generation of BM-cultured DCs
To test the production of cytokines by DCs, BM cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin and streptomycin in the presence of recombinant murine Flt3L (200 ng/ml) for 7-8 d to generate DCs. To generate the DCs used in the T-cell proliferation assay, the BM cells were cultured with Flt3L for 7-8 d, with additional GM-CSF (2 ng/ml) added to the cultures on day 6. All cytokines were purchased from PeproTech (Rocky Hill, NJ, USA).
T-cell proliferation assay
The OT-I CD8 + and OT-II CD4 + T cells were isolated from the spleens of OT-I or OT-II transgenic mice through the depletion of red blood cells and immune-magnetic bead negative selection (for CD8 + T-cell isolation, the mAb cocktail contained mAbs targeting CD11b, F4/80, B220, CD19, TER119, Ly6G, MHC-II and CD4; for CD4 + T-cell isolation, the mAb cocktail contained mAbs targeting CD11b, F4/80, B220, CD19, TER119, Ly6G, MHC-II and CD8). The isolated T cells were labeled using the CFSE cell proliferation kit (Invitrogen, Carlsbad, CA, USA).
Splenic CD8 + cDCs and CD8 − cDCs were sorted and incubated (1 × 10 5 cells/ml) with the ovalbumin (OVA) protein (100 μg/ml, Sigma, St Louis, MO, USA) or OVA peptide (OVA 257-264 , 1 ng/ml or OVA 323-339 , 1 μg/ml, Sigma) at 37°C. After 2 h, the cells were washed twice. Different numbers of DCs were plated in 96-well round-bottom plates. CFSE-labeled OT-I and OT-II T cells (1 × 10 5 cells/well) were incubated with CD8 + cDCs and CD8 − cDCs, respectively, in RPMI 1640 complete medium supplemented with 20 ng/ml GM-CSF. T-cell proliferation was analyzed by flow cytometry after 60-90 h.
Antigen presentation assay
DCs were isolated from the spleen and incubated with the OVA protein (100 μg/ml) for 2 h. Then, the free OVA protein was washed away and the cells were cultured for another 20 h. The DCs were stained using a biotin-conjugated anti-SIIN-FEKL/H-2Kb (eBioscience, San diego, CA, USA, eBio25-D1.16) antibody, followed by streptavidin-BV421 (eBioscience).
Antigen uptake assay Splenic DCs were incubated with AF488-labeled OVA protein (5 μg/ml, Invitrogen) at 37°C for 30 min. Uptake of the labeled OVA protein was measured by flow cytometry. DCs incubated on ice with the AF488-labeled OVA protein were used as the negative controls. 
Antigen degradation assay
Latex beads (Polysciences, Warrington, PA, USA) were activated with 8% glutaraldehyde (Sigma) at room temperature for 4-6 h, coupled with the OVA protein (0.5 mg/ml) at 4°C overnight, and blocked with glycine (0.5 M) at room temperature for 30 min.
DCs (0.5-1 × 10 6 ) were pulsed with the OVA-coated latex beads (cells:beads = 1:3) in a 37°C water bath for 30 min; then, phagocytosis was stopped with the addition of cold PBS. Noninternalized beads were removed by an FBS flotation gradient as follows. The cell suspension (1 ml) was layered over serum (2 ml) and centrifuged for 5 min at 150g. Then, the supernatant containing free beads was discarded. DCs were placed in RPMI 1640 complete medium supplemented with 20 ng/ml GM-CSF for the indicated times at 37°C. Then, the cells were lysed with 200 μl of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% NP40, and protease inhibitor cocktail, pH 7.4). The recovered latex beads were stained with a FITC-conjugated anti-OVA antibody (Rockland, Gilbertsille, PA, USA) at 4°C for 30 min and finally analyzed by flow cytometry.
T-cell cross-priming assay in vivo
To prepare cell-associated Ags, red blood cells were removed from splenocytes. The splenocytes were irradiated with a 30 Gy X-ray and coated with the OVA protein (1 mg/ml) at 37°C for 45 min; then, free Ag was washed away. The OVA-coated splenocytes (1 × 10 7 cells/mouse) were injected into the mice intravenously (i.v.). After 7 days, the mice were analyzed for the proliferation of OVA-specific CD8 + T cells in the spleen. To detect OVA-specific CD8 + T cells, the splenocytes were stained with the APC-labeled H-2Kb/SIINFEKL pentamer (Proimmune, Oxford, UK) for 30 min, followed by the anti-CD3 and anti-CD8 antibodies. The flow cytometry analysis was performed on the LSRII or LSRFortessa.
To examine the activation of T cells by soluble Ag in vivo, splenic CD8 + T cells were sorted from OT-I mice, stained with CFSE (Invitrogen), and then transferred (i.v. 7 × 10 5 cells/ mouse) to the recipients. After 24 h, the recipients were injected with the OVA protein (hypodermic injection 100 μg/ mouse) near both sides of the inguinal lymph nodes (50 μg/ side). After 36-48 h, the mice were killed to analyze the proliferation of OVA-specific CD8 + T cells (gated on CFSE + CD3 + CD8 + TCR Vα2 + ) in the inguinal lymph nodes.
Cell sorting by flow cytometry Cells isolated from the BM or spleen were incubated with rat immunoglobulin (Jackson Laboratories, West Grove, PA, USA) for 10 min and then stained with antibodies at 4°C for 30 min. The following mAbs were used for cell staining and sorting: PE-Cy7-conjugated CD11c (N418), PE-conjugated Siglec-H (eBio440c), CD3e (eBio500A2), CD40 (1C10), FITCconjugated CD86 (GL-1), APC-conjugated CD172α (P84), CD80 (16-10A1), eFluor 450-conjugated CD8α (53-6.7), CD24 (M1/69), CD4 (GK1.5), MHC-II (M5/114.15.2), BV 605-conjugated CD11b (M1/70) and AF 700-conjugated CD8 (53-6.7). All of the antibodies were purchased from eBioscience, BD Biosciences (Palo Alto, CA, USA) or BioLegend (San Diego, CA, USA). Dead cells were discriminated in all experiments using 7-AAD (eBioscience) staining. The analysis was performed on the LSRII and LSRFortessa flow cytometers. Cell sorting was performed on the FACSAria II or FACSAria III instrument (BD). The purity of the sorted populations was routinely greater than 95%. The data analysis was performed on the single live cell gate using the FlowJo software (TreeStar, Ashland, OR, USA).
Cytokine production assays BM-derived DCs (1 × 10 5 cells/well) or splenic DCs (5 × 10 4 cells/well) were seeded into 96-well plates and stimulated with TLR agonists, including 50 nM Pam2CSK4 (InvivoGen, San Diego, CA, USA, tlrl-pm2s-1), 50 nM Pam3CSK4 (InvivoGen, tlrl-pms), 100 μg/ml Poly (I:C) (InvivoGen, tlrl-pic), 100 ng/ml LPS (Sigma), 1 μg/ml R848 (InvivoGen, tlrl-r848), 10 nM ODN 1668 (AdipoGen, Liestal, Switzerland, IAX-200-001) and 1 μM ODN 2216 (AdipoGen, IAX-200-005). The medium used was RPMI 1640 supplemented with 10% FBS, 1% P/S (penicillin and streptomycin) and GM-CSF (20 ng/ml). Supernatants were collected after 24-36 h, and IL-12p40 and IL-12p70 were measured by ELISA. Recombinant mouse IL-12p70 (eBioscience, 14-8121) was used as the standard protein. Figure 1 The cross-presentation of soluble Ag by CD8 + cDCs from WT or p38α ΔDC mice. (a) p38α was abundantly expressed in cDCs. The p38α mRNA levels were measured by real-time PCR in different immune cells. (b) p38α was activated in splenic CD8 + and CD8 − cDCs after OVA treatment. DCs were sorted by flow cytometry and then stimulated with GM-CSF (20 ng/ml) and the OVA protein (100 μg/ml) as indicated. (c-e) Splenic CD8 + cDCs from WT or p38α ΔDC mice were coated with OVA 257-264 (1 ng/ml) or the OVA protein (100 μg/ml) for 2 h at 37°C; then, the CD8 + cDCs (0.25-1 × 10 4 /well) were incubated with CFSE-labeled OT-I CD8 + T cells (1 × 10 5 /well) in a 96-well plate for 60 h. T-cell proliferation was measured by flow cytometry analysis. The medium used was RPMI 1640 supplemented with 10% FBS, 1% P/S (penicillin and streptomycin) and GM-CSF (20 ng/ml). The percentage (c) and the number (d) of dividing T cells were reduced during co-culture with OVA-pulsed CD8 + DCs from p38α ΔDC mice. (e) The presentation abilities of OVA 257-264 by CD8 + cDCs from WT and p38α ΔDC mice were comparable. (f, g) Antigen presentation by Flt3L-supplemented BM cultured CD24 + cDCs from WT or p38α ΔDC mice were measured as described in c-e. 
Real-time PCR for gene expression
The total RNA extraction and reverse transcription procedures were performed as previously described. 26 Real-time PCR was performed with SYBR Green I on the 7900 real-time PCR detection system (Applied Biosystems, Grand Island, NY, USA) using the following conditions: denaturation, 95°C, 15 s; annealing, 55°C, 20 s; and extension, 72°C, 25 s. The primers used for the mouse Nox2 gene were 5′-TGTGGTTGGGGCTG AATGTC-3′ and 5′-CTGAGAAAGGAGAGCAGATTTCG -3′. The primers used for the mouse TAP1 gene were 5′-GGA CTTGCCTTGTTCCGAGAG-3′ and 5′-GCTGCCACATAAC TGATAGCGA-3′. The primers used for the mouse GAPDH gene were 5′-TGTGTCCGTCGTGGATCTGA-3′ and 5′-CCT GCTTCACCACCTTCTTGA-3′.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5. The data were presented as the mean ± s.e.m. Statistical significance was determined by the one-tailed unpaired Student's t-test. Differences were considered statistically significant when Po0.05.
RESULTS

p38α deficiency impaired the antigen cross-presentation ability of CD8 + cDCs
To investigate the role of p38α in immune cells, we first tested p38α expression in different immune cell types. We observed that p38α was highly expressed in splenic CD8 + cDCs and CD8 − cDCs but weakly expressed in pDCs, macrophages, T cells (CD4 + and CD8 + ) and B cells (Figure 1a ), which suggested that p38α might be important for cDC functions. Because the most important function of cDCs is Ag presentation, we examined whether the expression and phosphorylation of p38α were affected after cDCs encountered Ag. Splenic CD8 + and CD8 − cDCs were cultured with the OVA protein or GM-CSF alone or in combination for various times; then, p38α phosphorylation (the activated form of p38α) was measured. Because DCs are short-lived cells and can rapidly lose their antigen presentation ability, GM-CSF was added to the culture medium to sustain DC viability and functionality. Both the CD8 + and CD8 − cDCs showed significantly elevated p38α activation levels after the OVA and GM-CSF treatments, especially at 60 min for the CD8 + cDCs and 30 min for the CD8 − cDCs (Figure 1b) . Although p38α could be activated by either OVA or GM-CSF alone, the phosphorylated level of p38α in the OVA-treated (100 μg/ml) cDCs was much stronger than the level in the GM-CSF-treated (20 ng/ml) cDCs (Figure 1b ). These data suggested that activation of p38 signaling might be important for antigen presentation by cDCs.
To examine the involvement of p38α in DC functions, we investigated whether deletion of p38α in cDCs affected their Ag presentation ability. For this purpose, mice with a conditional p38α deletion in DCs (p38α ΔDC mice) were generated by crossing CD11c-cre mice to p38α fl/fl mice. p38α expression was almost completely abrogated in the splenic pDCs, CD8 + cDCs and CD8 − cDCs (Supplementary Figure S1a) . Because splenic CD8 + cDCs are specialized for antigen cross-presentation, first we tested the effect of p38α deficiency on the crosspresentation ability of CD8 + cDCs. Splenic CD8 + cDCs were pulsed with the OVA protein or peptide and then incubated with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled OT-I CD8 + T cells. The number of divided T cells (recognized by reduced CFSE fluorescence) after 60 h was used as a measure of the Ag cross-presentation ability of the CD8 + cDCs. The results showed that the percentage of dividing T cells was reduced during co-culture with OVA-pulsed CD8 + cDCs from the p38α ΔDC mice compared with the WT mice (Figure 1c) . Further analysis showed that the number of dividing OT-I CD8 + T cells was also decreased in the cultures with different numbers of p38α-deficient DCs (Figure 1d ), indicating that the CD8 + cDCs from the p38α ΔDC mice had a lower cross-presentation capacity than the CD8 + cDCs from the WT mice. However, the presentation of the OVA peptide by the CD8 + cDCs (which would not require Ag uptake and processing) from the p38α ΔDC mice was comparable to the presentation of the CD8 + cDCs from the WT mice (Figures 1c and e), indicating that the antigen presentation ability per se was not affected. We also examined the effects of p38α deficiency on the ability of the CD8 + cDCs to directly present the OVA protein to the OT-II CD4 + T cells. No significant differences were observed between CD8 + cDCs from the p38α ΔDC and WT mice in terms of the percentages (Supplementary Figure S1b) and numbers (Supplementary Figure S1c and d) of dividing T cells, suggesting that p38α had little effect on the direct presentation ability of the CD8 + cDCs.
To confirm the function of p38α in the regulation of the cDC Ag presentation ability, bone marrow (BM) cell-derived cDCs from the WT and p38α ΔDC mice were utilized in the T-cell proliferation assay. The Flt3L-supplemented BM cultures generated three DC subsets, including pDCs, CD24 + cDCs (equivalent to splenic CD8 + cDCs) and CD24 − cDCs (equivalent to splenic CD8 − cDCs). Consistent with the observations in splenic cDCs, the cross-presentation ability of the CD24 + cDCs derived from p38α ΔDC mouse BM cells was markedly reduced compared with the WT mouse cells (Figure 1f ). Even with increasing numbers of OVA-pulsed CD24 + cDCs in culture, only low numbers of dividing T cells could be detected after 60 or 80 h (Figure 1g ). Moreover, IFN-γ production was significantly reduced in the supernatant of the p38α-deficient CD24 + cDC and OT-I CD8 + T-cell co-culture (Figure 1h) , which was another indication of impaired T-cell activation. We also performed a T-cell proliferation assay using splenic and BM-derived cDCs from hematopoietic cell-specific p38α-deficient (Vav-cre +/-p38α fl/fl , p38α ΔHPC ) mice and observed similar results ( Supplementary Figures S1e and f) . Overall, these data indicated an important role for p38α in Ag cross-presentation by CD8 + cDCs.
p38α deletion reduced the direct antigen presentation capacity of CD8 − cDCs In addition to CD8 + cDCs, the mouse spleen contains CD8 − cDCs, which have been shown to be efficient antigen (Figures 2a and b) , whereas the presentation of the OVA peptide was not affected (Figures 2a and c) . The unchanged ability to present a peptide antigen by the p38α-deficient CD8 − cDCs suggested that the defective direct presentation capacity was not the result of the defective presentation of antigen peptides. Similarly, deletion of p38α reduced the direct presentation ability of CD24 − cDCs derived from BM, which were equivalent to splenic CD8 − cDCs (Figures 2d and e) . In addition, we used CD8 − cDCs from the spleen (Supplementary Figure S2a) and CD24 − cDCs (Supplementary Figure S2b) derived from BM cells from the p38ɑ ΔHPC mice and found that their OVA protein presentation abilities were also decreased. These results indicated that p38α was an important regulator of Ag direct presentation by CD8 − cDCs.
p38α was not required for the upregulation of co-stimulatory molecules on cDCs Antigen-specific T-cell activation by DCs requires the expression of several co-stimulatory molecules by DCs, such as CD80, CD86 and CD40. To investigate whether the reduction of T-cell proliferation in the co-cultures with Ag-pulsed splenic DCs from p38α ΔDC mice was due to a defect in the expression of co-stimulatory and MHC molecules, we determined the CD80, CD86, CD40, MHC-I and MHC-II expression levels on splenic DCs from the p38α ΔDC and WT mice. Comparable levels of these molecules were expressed by WT and p38α ΔDC cDCs without any stimulation (Figure 3a) . Moreover, when sorted splenic cDC subsets from the WT and p38α ΔDC mice were pulsed with the OVA protein for 20 h (Figure 3b ) or stimulated with a TLR agonist (Pam2 or CpG) for 16 h (Supplementary Figure S3a) , the expression levels of the co-stimulatory and MHC molecules were also comparable between the p38α-deficient and WT cDCs after stimulation. This result suggested that the upregulation of these molecules by DCs did not require p38α.
In addition to the expression of co-stimulatory molecules, the survival status of DCs could also affect the efficiency of DC antigen presentation. Therefore, we examined the survival status of splenic CD8 + and CD8 − cDCs from the p38α ΔDC and WT mice after stimulation with TLR agonists or a pulse with the OVA protein for various times. No significant differences in cell survival were observed between the cDCs from the p38α ΔDC and WT mice (Supplementary Figures S3b  and c) , confirming that the differences in T-cell proliferation induced by the p38α ΔDC cDCs were not due to increased cell death of the p38α ΔDC DCs. Consistent with the OVA peptide presentation by DCs, these data suggested that p38α did not influence the DC Ag presentation ability at the co-stimulation level.
p38α deletion led to decreased Nox2 expression and excessive antigen degradation in the CD8 + cDCs As shown above, p38α deficiency did not significantly affect the co-stimulation of T cells by DCs. Therefore, we speculated that p38α might regulate the cross-presentation of OVA by CD8 + cDCs. First, we compared the Ag peptide and MHC-I complex levels on the surface of the CD8 + cDCs from the p38α ΔDC and WT mice using an antibody that bound to the OVA 257-264 /H-2Kb complex, which was the same OVA peptide/MHC-I complex recognized by the OT-I CD8 + T cells. The CD8 + cDCs were incubated with the OVA protein for 2 h, and free protein was washed away; then, the DCs were stained for the OVA 257-264 /H-2Kb complex on the surface 20 h later. The WT control CD8 + cDCs showed a moderate level of staining over the background (DCs without OVA protein incubation), whereas the p38α-deficient CD8 + cDCs showed very little positive staining above the background (Figure 4a ). These results suggested that the decreased OT-I CD8 + T-cell proliferation induced by the p38α-deficient CD8 + cDCs was the result of decreased formation of the OVA 257-264 /H-2Kb complex on the cell surface, resulting in decreased crosspresentation of the OVA antigen by the p38α-deficient CD8 + cDCs.
The reduced formation of the OVA peptide/MHC-I complex on the surface and the decreased Ag presentation by the p38α-deficient cDCs could be the result of decreased Ag uptake or deficient Ag processing by these cDCs. To test whether the Ag uptake was also affected by the p38α deficiency, splenic cDCs were isolated and incubated with the AF488-conjugated OVA protein at 37°C for 30 min, and the uptake of the labeled OVA protein was measured by flow cytometry. Both the CD8 + and CD8 − cDCs from the p38α ΔDC mice showed similar uptake of the OVA protein into cells compared to that from WT mice (Figure 4b ). These results indicated that the defect in Ag presentation by the p38α-deficient DCs was not at the Ag uptake stage.
To determine whether the defect in Ag cross-presentation by the p38α-deficient CD8 + cDCs was due to impaired Ag processing, we tested the effects of p38α on the expression of a few molecules important for Ag processing and presentation. We focused on two important molecules known to be involved in antigen processing during cross-presentation: NADPH oxidase 2 (Nox2), which is an essential regulator of phagosomal protease activity that limits Ag degradation, and transporter associated with Ag processing 1 (TAP1), which is an important transporter for Ag peptides into the endoplasmic reticulum (ER) or phagosome for subsequent loading onto MHC-I molecules. CD8 + and CD24 + cDCs were incubated with the OVA protein, followed by real-time PCR analysis to determine the Nox2 and TAP1 mRNA levels. As shown in Figures 4c and d , Nox2 and TAP1 expressions were significantly reduced in the CD8 + and CD24 + cDCs from the p38α ΔDC mice compared with the cells from the WT mice after 6 or 12 h of incubation with OVA. Similar results were found in the CD24 + cDCs derived from BM cells from p38ɑ ΔHPC mice (Supplementary Figure S4a) . After phagocytosis of the Ags, DCs execute an Figure 2 The comparison of Ag direct presentation by CD8 − cDCs from WT or p38α ΔDC mice. (a-c) Splenic CD8 − cDCs from the WT or p38α ΔDC mice were pulsed with OVA 323-339 (1 μg/ml) or OVA protein (100 μg/ml) for 2 h at 37°C; then, the CD8 − cDCs (0.25-1 × 10 4 /well) and CFSE-labeled OT-II CD4 + T cells (1 × 10 5 /well) were incubated together for 85 h. OT-II T-cell proliferation was measured by flow cytometry. The medium used was RPMI 1640 supplemented with 10% FBS, 1% P/S (penicillin and streptomycin) and GM-CSF (20 ng/ml). (a, b) The OT-II T-cell proliferation activated by OVA-pulsed p38α-deficient CD8 − cDCs was reduced compared with the control cells. (c) Similar levels of OVA 323-339 presentation by CD8 − cDCs from WT and p38α ΔDC mice. (d, e) BM-derived CD24 − cDCs from WT or p38α ΔDC mice were pulsed with OVA 323-339 (1 μg/ml) or OVA protein (100 μg/ml) for 2 h; then, CD24 − cDCs (0.25-1 × 10 4 /well) and CFSE-labeled OT-II CD4 + T cells (1 × 10 5 /well) were incubated together for 60 and 80 h. (a-c) The CD8 − cDCs were sorted from five pairs of littermate mice. (d, e) The CD24 − cDCs were derived from BM cells of three pairs of littermate mice. All of the in vitro experiments were repeated three times, and the results shown were representative. The results were presented as the mean ± s.e.m. *Po0.05; **Po0.01; ***Po0.001. Peptides with a suitable size for insertion into the MHC-I peptide binding groove are required for efficient Ag crosspresentation; these peptides are typically approximately eight to nine amino acids in length. 7 Excessive Ag degradation would reduce the number of suitable peptides and diminish the potential epitopes for T-cell recognition. Nox2 was shown to regulate the phagosome pH in DCs to induce alkalization of the phagosomes (pH = 7-7.5) via control of ROS (reactive oxygen species) production, which protected the Ags from excessive degradation by proteases (most of which have optimal activity at pH 5.5-6.5). Nox2-defective DCs showed enhanced phagosomal acidification, which led to elevated proteolytic activity of the proteases, immoderate antigen degradation, and defective cross-presentation. Next, we evaluated the functional consequences of decreased Nox2 expression on Ag degradation. We performed an Ag degradation assay using latex beads covalently coupled with the OVA protein, which could be selectively degraded in phagosomes. BM-derived CD24 + cDCs were pulsed with the beads for 30 min (pulse time). Then, the beads were washed away. The cells were incubated for another 8 h (chase time) and disrupted in lysis buffer for the isolation of the endocytosed beads. The amount of OVA protein remaining on the beads was measured with an OVA-specific antibody by flow cytometry. We observed that the degradation of the OVA protein was clearly increased in the p38α-deficient CD24 + cDCs, which exhibited a marked decrease in Nox2 expression over time compared with the wild-type DCs after a 30-min pulse and 8 h chase (Supplementary Figures S4b and e) . Consequently, the excessive degradation of Ag might lead to inefficient antigen cross-presentation by p38α-deficient The co-stimulatory molecule expression on splenic CD8 + cDCs and CD8 − cDCs from WT or p38α ΔDC mice after incubation with OVA for 20 h. The gray shadows were isotype controls. The medium used was RPMI 1640 medium supplemented with 10% FBS, 1% P/S (penicillin and streptomycin) and GM-CSF (20 ng/ml). The DCs were sorted from 5 pairs of littermate mice. The data were representative of two independent experiments, each including duplicated samples.
p38α positively regulates antigen cross-presentation Y Zhou et al CD24 + cDCs. Taken together, our data suggested that the reduction of p38α-dependent expression of Nox2 at least partially accounted for the defective Ag cross-presentation ability of the p38α-deficient CD24 + cDCs.
p38α was required for cross-priming of antigen-specific CD8 + T lymphocytes in vivo To confirm that the decreased Ag cross-presentation by p38α-deficient CD8 + cDCs in vitro also affected the activation of CD8 + T cells in vivo, we tested the activation of OVA-specific CD8 + T cells in vivo by injecting WT and p38α ΔDC mice with OVA-coated X-ray-irradiated splenocytes and analyzed the proliferation of OVA-specific CD8 + T cells in the spleen after 7 days (Figure 5a) . The results showed that the percentages (Figures 5b and c) and numbers (Figure 5d ) of these OVAspecific T cells (gated on the CD8 + OVA 257-264 /H-2Kb pentamer + ) were substantially reduced in the p38α ΔDC mice compared with the WT mice, demonstrating that p38α was were cultured with OVA-coated latex beads (3 × 10 6 ) for 30 min to allow phagocytosis, followed by removal of the free beads as described in the Methods. Then, the CD24 + cDCs were disrupted by lysis buffer immediately (0 h) or after another 8 h of culture (8 h (a) Splenocytes were irradiated by a 30 Gy X-ray, coated with OVA (1 mg/ml) at 37°C for 45 min, and then free Ag was washed off. Then, the OVA-coated splenocytes (1 × 10 7 cells/mouse) were injected into the mice intravenously (i.v.). The proliferation of OVA-specific OT-I CD8 + T cells in the spleens of the injected mice was measured 7 days later using the APC-labeled MHC-I/SIINFEKL pentamer. The percentages (b, c) and numbers (d) of OVA-specific CD8 + T cells in the WT (n = 5) and p38α ΔDC mice (n = 4) are presented. (e) CFSE-labeled OT-I CD8 + T cells (7 × 10 5 cells/mouse) were transferred to the WT and p38α ΔDC mice (i.v.). After 24 h, OVA protein (100 μg/mouse) was subcutaneously injected in the recipients at sites near the inguinal lymph nodes (OVA protein, 50 μg/site). A PBS injection was used as a negative control. After 36-48 h, two inguinal lymph nodes were collected from the recipients and analyzed for OVA-specific T-cell proliferation. The percentages (f, g) and numbers (h, i) of OVA-specific CD8 + T cells in the WT and p38α ΔDC mice are presented (WT n = 5 and p38α ΔDC n = 5 for the OVA protein-injected group; WT n = 2 and p38α ΔDC n = 2 for the PBS-injected group). The results are presented as the mean ± s.e.m. *Po0.05; **Po0.01; ***Po0.001. crucial for the cross-presentation of cell-associated antigens and the activation of cytotoxic T cells by CD8 + cDCs.
To confirm the role of p38α in the cross-priming of T cells, we adoptively transferred CFSE-labeled OT-I CD8 + T cells to WT and p38α ΔDC mice, which excluded potential defects of the CD8 + T cells in the p38α ΔDC mice. After 24 h, the recipients were injected subcutaneously with the OVA protein. Within 36-48 h after OVA administration, the proliferation of OVAspecific OT-I T cells was determined in the draining lymph nodes of the recipients (Figure 5e ). Rapid and robust proliferation of OVA-specific T cells was observed in the WT mice. In contrast, impaired proliferation of OVA-specific T cells (gated on CFSE + CD3 + CD8 + TCR Vα2 + ) was observed in the p38-deficient mice (Figures 5f-i) . These data confirmed that p38α was required for the efficient activation of T cells by both cell-associated and soluble Ags.
p38α was required for the normal production of IL-12 by cDCs The cytokines produced by cDCs during antigen presentation also contribute to the activation of antigen-specific T cells. Therefore, we tested whether p38α also affected cytokine production by cDCs.
Among the mouse splenic cDCs, CD8 + cDCs are the major producers of IL-12p70, whereas CD8 − cDCs produce a large amount of IL-12p40. IL-12p70 is composed of the IL-12p40 and IL-12p35 subunits. 27 IL-12 can enhance CD8 + T-cell proliferation in antiviral CTL responses 28 and can augment CTL activity through the increase in the perforin levels. 29 To test whether p38α also regulated the production of IL-12, we analyzed TLR-triggered production of IL-12p40 and IL-12p70 by p38α-deficient cDCs. The CD24 + cDCs from the Flt3L-supplemented BM cultures were stimulated with a panel of TLR ligands in vitro, including Pam2 (TLR2/6), Pam3 (TLR2/1), polyIC (TLR3), LPS (TLR4), R848 (TLR7), CpG1668 and CpG2216 (TLR9). The CD24 + cDCs from the p38α ΔDC mice produced considerably lower amounts of IL-12p40 and IL-12p70 (Figures 6a and b ) in response to CpGs compared with the cells from the WT mice. Similarly, IL-12p40 production by the p38α-deficient CD24 − cDCs was significantly reduced after stimulation by TLR9 agonists (Figure 6c ). To confirm that similar results could be obtained with ex vivo DC subsets, we sorted splenic CD8 + and CD8 − cDCs and stimulated them separately with CpGs. Similar results were observed with defective production of IL-12p40 and IL-12p70 by the p38α-deficient splenic CD8 + cDCs (Figures 6d and e) and impaired production of IL-12p40 by the p38α-deficient splenic CD8 − cDCs (Figure 6f ). Our results were in line with a previous report that p38 inhibitors reduced CD40 or LPS-induced production of IL-12 by MoDCs. 30, 31 Therefore, we provided specific evidence for a role of p38α as an essential regulator of IL-12 production by cDCs. 
DISCUSSION
The p38 signaling pathway has been established as an important mediator of intracellular signaling during the innate and adaptive immune responses. Although the role of p38 signaling in DCs has been investigated in detail, most studies focused on its regulatory function in cytokine production. For instance, p38 inhibitors suppressed the production of IL-12p40, IL-12p70, IL-6 and TNF-a by MoDCs upon stimulation by the CD40 ligand 16 or LPS, 30 and the high-mobility group box protein 1 induced IL-6 secretion by MoDCs via a p38 MAPKdependent pathway. 32 These cytokines secreted by DCs are important for the differentiation and expansion of T cells. 33, 34 Recent studies reported that p38α programmed DCs to promote Th17 differentiation during autoimmune neuroinflammation. 20, 35 Deletion of p38α led to decreased IL-6 production but increased IL-27 expression by DCs, which impaired IL-17 and IL-23R expression in T cells. 20, 35 Moreover, the DC-intrinsic p38α function was important for the differentiation of induced regulatory T cells (iTregs) and Th1 cells. p38α deficiency in mesenteric lymph node CD103 + DCs substantially diminished TGF-β2 expression, which impaired the generation of iTregs but promoted Th1 differentiation during mucosal immune tolerance. 22 However, the role of p38 signaling in the most characteristic function of DCs (Ag presentation) has not been thoroughly investigated. Some studies reported that TLR signaling enhanced the DC Ag capture ability, which could be blocked by the p38 inhibitor SB203580. 36 However, whether p38 MAPK also directly participated in Ag presentation of DCs at steady state without TLR activation was unknown. Therefore, in this study, we investigated the role of p38α in Ag presentation by DCs and reported for the first time that p38α had an important role in the cross-presentation of CD8 + cDCs and had a moderate effect on the direct presentation ability of CD8 − cDCs. Conversely, the direct presentation ability of CD8 + cDCs was not significantly affected by p38α deficiency. This varying influence on the direct presentation ability of two cDC subsets might be due to the characteristics of the cells themselves because CD8 − cDCs were reported to be more efficient than CD8 + cDCs at direct presentation of the soluble OVA protein via the MHC class II pathway. 37, 38 Moreover, we found that p38α deficiency led to excessive Ag degradation and a subsequent reduction in Ag cross-presentation by CD8 + cDCs without affecting Ag uptake or co-stimulation. The dispensable role of p38α in Ag uptake was also demonstrated in other reports; for instance, the phagocytosis of citrobacter rodentium by DCs was not regulated by p38α. 39 Furthermore, we demonstrated that p38α was important for the activation of OVA-specific CD8 + T cells in vivo. This finding was supported by other studies that demonstrated that the DC intrinsic function of p38α was crucial for hapten-specific CD8 + T-cell priming and skin inflammatory responses. This effect accounted for a much lower level of TLR2-triggered CCL7 by p38α-deficient DCs, which led to a reduced interaction between DC and T cells and resulted in failure of T-cell priming. 40 The antigen cross-presentation is involved in many immune responses, including responses to viral infections, tumors and transplants. 41, 42 Upon uptake, antigen proteins are partially degraded in phagosomes. Then, the antigens access the cytosol, where they are degraded into peptides by the proteasome. The peptides are transported by TAP1 into the ER lumen 43 or phagosomes [44] [45] [46] for loading onto MHC-I molecules. 47 The function of TAP1 in antigen presentation has been extensively studied (for example, TAP1 − / − DCs exhibited defective peptide translocation 45 and OVA cross-presentation ability 48 and TAP deficiency led to defective stable assembly and intracellular transport of MHC-I molecules, resulting in a failure to present cytosolic antigens to CD8 + cytotoxic T cells). 49 Although p38α-deficient CD8 + cDCs had a defect in the upregulation of the TAP1 mRNA level during Ag presentation, this defect did not lead to defective MHC-I expression as observed in TAP1-deficient mice, 49 suggesting that the reduced TAP1 mRNA level might not be the dominant factor leading to the defective cross-presentation by p38α-deficient CD8 + cDCs. For efficient antigen cross-presentation, peptides of suitable size with proper immunogenicity and a sufficient quantity must be generated under a precisely controlled process. The antigenic peptide for cross-presentation is approximately eight to nine amino acids in length, which is suitable for insertion into the MHC-I peptide binding groove. 7 Exacerbated Ag degradation would damage potential T-cell epitopes and decrease the amount of antigenic peptides, which is detrimental for Ag crosspresentation. Recent studies demonstrated a pivotal role for Nox2 in the regulation of antigen degradation and the crosspresentation ability of DCs. 50, 51 Nox2 generates superoxides in the lumens of phagosomes, which react with H + to make hydrogen peroxide and ROS. 52 Consequently, the DC phagosome is sustained in an alkalescent environment, leading to a low degree of proteolytic activity that helps to avoid excessive Ag degradation and to guarantee a sufficient array of peptides for presentation. 53 Nox2 − / − DCs of both mouse 48 and human 54 origin presented enhanced phagosomal acidification and excessive antigen degradation, resulting in markedly decreased antigen cross-presentation. However, the mechanism by which the expression or functions of Nox2 are regulated during Ag processing and presentation is not completely understood. Here we showed that deletion of p38α resulted in a reduction in the expression of Nox2 in CD8 + cDCs, which might lead to enhanced Ag degradation and inefficient antigen cross-presentation. In line with our results, a number of studies revealed that p38α had a role in the expression and activation of Nox2. In the heart and aorta, a p38 inhibitor significantly suppressed both Nox2 mRNA expression and ROS generation, which helped to protect the rat against the hypertension and organ damage induced by Angiotensin II. 55 Moreover, p38 was required for activation of the NADPH oxidase (composed of Nox2, p67 phox, p22 phox and p47 phox) and the production of ROS induced by hyperoxia in human lung endothelial cells; 56 p38 was also shown to regulate NADPH oxidase activity and O 2 − generation in bovine polymorphonuclear leukocytes. 57 Activation of p38 mediated S100A8/A9 translocation, leading p38α positively regulates antigen cross-presentation Y Zhou et al to Nox2 activation in neutrophils. 58 In addition, studies of the hepatitis C virus nonstructural protein 3-induced oxidative burst demonstrated the involvement of p38 signaling in NADPH oxidase activation and the generation of ROS in human monocytes. 59 All of these studies suggested an important role for p38-mediated Nox2 activation in various physiological processes. Our study provided new evidence for the importance of p38α-dependent Nox2 in DC functions, which at least partially accounted for the impaired Ag crosspresentation by DCs and the subsequent T-cell activation. Further studies are required to investigate how p38α exerts its effects on the expression and function of Nox2.
GM-CSF-induced MoDCs, which are equivalent to DCs under inflammatory conditions, were used in most previous studies. 60 Our study examined the role of p38α in the functions of DCs in the mouse spleen or derived from Flt3L-BM cultures, which presented the majority of DCs in lymphoid tissues under a steady state. 11, 61 Similar defects in Ag processing and presentation were observed in p38α-deficient DCs from both sources, confirming an important role for p38α in regulating the functions of DCs in lymphoid tissues.
In summary, our study provided evidence that p38α in DCs is a critical regulator of Ag cross-presentation and IL-12 production. The novel information obtained in our study should facilitate our understanding of the key molecular mechanisms that regulate the Ag presentation process and help with the development of novel therapeutic strategies for the treatment of infectious diseases and tumors.
